HealthEquity EVP Disposes 6,000 HQY Shares via 10b5-1 Plan
Rhea-AI Filing Summary
Insider sale under 10b5-1 plan: Ladd Delano, Executive Vice President and General Counsel of HealthEquity, Inc. (HQY), reported dispositions of company common stock on 09/19/2025 executed under a Rule 10b5-1 trading plan adopted June 12, 2025. The filings show three sell transactions totaling 6,000 shares at weighted-average prices of $93.9137, $95.0603 and $95.70. Following these transactions the reporting person beneficially owned 79,456 shares. The filer signed the Form 4 on 09/22/2025.
Positive
- Transactions executed under a Rule 10b5-1 trading plan, adopted June 12, 2025, providing an affirmative defense to insider trading claims
- Form 4 filed and signed promptly (signed 09/22/2025), meeting disclosure requirements
Negative
- Insider dispositions totaling 6,000 shares on 09/19/2025, reducing reported beneficial ownership to 79,456 shares
- Sales occurred at market prices (weighted averages reported $93.9137 and $95.0603; one sale at $95.70), which may be perceived by some investors as insider selling
Insights
TL;DR: Insider sold 6,000 shares under a pre-established 10b5-1 plan; disclosure is routine and reduces insider holdings modestly.
The transactions were executed pursuant to a 10b5-1 plan adopted June 12, 2025, which provides an affirmative defense to insider trading claims when properly structured. The disposition pattern—multiple executions on the same date at weighted-average prices—fits routine plan-based selling rather than ad-hoc trades. The post-transaction beneficial ownership of 79,456 shares represents a modest reduction from pre-transaction holdings. From a governance standpoint, timely Form 4 reporting and plan disclosure are best practices that reduce regulatory risk.
TL;DR: The sale of 6,000 shares at roughly $94–$95 is a small, disclosed insider disposition executed under a trading plan; market impact is likely negligible.
Aggregate shares sold equal 6,000 across three reported dispositions on 09/19/2025 with weighted-average prices disclosed for two groupings and a single-share-weighted price for the third. The use of a 10b5-1 plan suggests pre-scheduled dispositions rather than opportunistic selling. Given the size relative to total reported beneficial ownership (79,456 shares remaining), the trades are unlikely to materially affect valuation or signal significant insider concern based solely on the Form 4.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 5,000 | $93.9137 | $470K |
| Sale | Common Stock | 971 | $95.0603 | $92K |
| Sale | Common Stock | 29 | $95.70 | $3K |
Footnotes (1)
- The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.52 to $94.51 inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 of this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.70 to $95.67 inclusive.
